Selected article for: "China clinical trial and clinical trial"
Author: Xiaohua Chen; Binghong Zhao; Yueming Qu; Yurou Chen; Jie Xiong; Yong Feng; Dong Men; Qianchuan Huang; Ying Liu; Bo Yang; Jinya Ding; Feng Li
Title: Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients
  • Document date: 2020_3_3
    • ID: g41pd9uz_32
    Snippet: Our research indicated that serum SARS-CoV-2 viral load and IL-6 level could serve as an indicator of poor prognosis. Since the mortality of COVID-19 critically ill patients is considerable, the host-directed therapies should be an option. If IL-6 could become a therapeutic target for treatment of critically ill patient? Notably, the IL-6 monoclonal antibody-directed COVID-19 therapy has been used in clinical trial in China (No.ChiCTR2000029765)......
    Document: Our research indicated that serum SARS-CoV-2 viral load and IL-6 level could serve as an indicator of poor prognosis. Since the mortality of COVID-19 critically ill patients is considerable, the host-directed therapies should be an option. If IL-6 could become a therapeutic target for treatment of critically ill patient? Notably, the IL-6 monoclonal antibody-directed COVID-19 therapy has been used in clinical trial in China (No.ChiCTR2000029765). Our data strongly support this notion and efficacy of IL-6 monoclonal antibody directed therapy remains to be fully evaluated.

    Search related documents:
    Co phrase search for related documents
    • antibody direct and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7
    • antibody direct and monoclonal antibody direct: 1, 2, 3, 4, 5, 6
    • clinical trial and critically ill patient: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical trial and critically ill patient mortality: 1
    • clinical trial and fully evaluate: 1, 2, 3, 4
    • clinical trial and host direct: 1, 2, 3, 4
    • clinical trial and level SARS viral load: 1
    • clinical trial and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and poor prognosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • clinical trial and poor prognosis indicator: 1
    • clinical trial and SARS viral load: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and therapeutic target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • critically ill patient and monoclonal antibody: 1, 2, 3
    • critically ill patient and poor prognosis: 1, 2, 3, 4
    • critically ill patient mortality and poor prognosis: 1, 2
    • fully evaluate and monoclonal antibody: 1
    • host direct and monoclonal antibody: 1, 2
    • host direct and SARS viral load: 1
    • level SARS viral load and SARS viral load: 1, 2, 3, 4, 5